RSS YouTube Flickr
News

WADA confirms agenda for Paris Pharmaceutical Conference

October 3, 2012

WADA has confirmed the agenda for the international pharmaceutical conference on doping in sport to be held in Paris on November 12.

‘The Pharmaceutical Industry and the Fight against Doping: New Partnerships for Clean Sport’ is co-organized by hosts the Ministry of Sports, Youth, Non Formal Education and Voluntary Organizations of France, the Council of Europe, UNESCO and WADA.

It will also feature representatives from the International Olympic Committee (IOC) International Federation of Pharmaceutical Manufacturers Association (IFPMA), the Biotechnology Industry Organization (BIO) and some of the leading pharmaceutical companies worldwide.

WADA can also confirm that there has been a change of venue and the Conference will now be held at:

French Parliament House:
Chaban-Delmas Building, Room Victor Hugo
101 rue de l’Université 75007, Paris

The Conference will run from 09:00 – 17:30 and consists of two sessions. The morning session will focus on the issue of doping in sport and the societal consequences it has for the pharmaceutical and health industries.

The second session in the afternoon has been designed to explore a framework in which anti-doping organizations, in particular WADA, and the pharmaceutical industry can work together to tackle the problem.

Provisional AGENDA

FIRST SESSION: The Pharmaceutical Industry and WADA: Uniting for Clean Sport

Opening

Ms Valérie Fourneyron, Minister of Sports, Youth, Non Formal Education and Voluntary Organisations, France
Hon. John Fahey, President, World Anti-Doping Agency (WADA)
Ms Gabriella Battaini-Dragoni, Deputy Secretary General, Council of Europe
Mr Getachew Engida, Deputy Director General, UNESCO
Dr Jacques Rogge, President, International Olympic Committee (IOC)

Part 1: Societal and economic risks of doping

Mr David Howman, Director General, WADA
Mr Philippe Lamoureux, Director General, LEEM, and Council Member of the International Federation of Pharmaceutical
Manufacturers and Associations (IFPMA)

Part 2: Health industry and anti-doping authorities: what is at stake in the cooperation?

Prof. Arne Ljungqvist, Vice President, WADA
Ms Patricia Brunko, Head of Unit, Directorate General of Health and Consumers (DG SANCO), European Commission
Mr Philip Thomson, Senior Vice President, Global Communications, GlaxoSmithKline
Mr James C. Greenwood, President and CEO, Biotechnology Industry Organisation (BIO)

Part 3: Health industry and anti-doping authorities: past experiences and lessons learnt

Dr Olivier Rabin, Science Director, WADA
Dr Philippe Van Der Auwera, Global Head of Drug Safety, Roche

Close: The way forward

Hon. John Fahey, President, World Anti-Doping Agency (WADA)

——-

SECOND SESSION: Presentation of the operational framework to the parties concerned (public authorities and pharmaceutical firms) to ensure their effective involvement

Round table 1: From the political concept to raising awareness among those involved: what kind of network to build and how to include all the stakeholders?

Moderator: Prof. Arne Ljungqvist, WADA
Rapporteur: Ms Patricia Brunko, European Commission

Panelists:
Dr. Laetitia Bigger, Regulatory and Scientific Affairs Manager, IFPMA
Representative from LEEM (tbc)
Mr Andy Parkinson, Chief Executive, UK Anti-Doping
Mr Andrew Emmett, Managing Director, Science and Regulatory Affairs, US BIO
A representative of EMA (tbc)

Round table 2: What framework is needed for co-operation between the World Anti-Doping Agency and stakeholders in the health sector? Lessons learnt: from raising awareness to implementation

Moderator: Dr Steve Elliott, Amgen
Rapporteur: Mr Marc de Garidel, Chairman, G5 Group

Panelists:
Ms. Barbara Leishman, Head of Safety Science Quality Risk Management, Roche
Ms. Elodie McNeil, Director Regulatory Policy and Intelligence, Abbott
Mr Mark Luttmann, WADA Cooperation Coordinator, GlaxoSmithKline
Representative biotechnology company (tbc)
Dr. Olivier Rabin, Director Science, WADA

Summary: How to build on the work already done and further develop co-operation through an action programme?

General Rapporteurs:
Mr David Howman, WADA
Mr Bruno Genevois, President, Agence française de lutte contre le dopage (AFLD)
Media interested in registering for this event please contact:

Terence O’Rorke
WADA Senior Manager, Media Relations and Communications
E: media@wada-ama.org
T: +1 514 904 8820